Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOX1 | Q06278 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL777194 | 0.89 | AOX1 (0.66) | AOX1MEN1KMT2AACHEL3MBTL1 | |
| SCHEMBL5488445 | 0.87 | MEN1 (0.65) | AOX1MEN1KMT2AACHEL3MBTL1 | |
| SCHEMBL28693406 | 0.86 | AOX1 (0.62) | AOX1NPSR1ALDH1A1 | |
| SCHEMBL27925108 | 0.85 | AOX1 (0.66) | AOX1MEN1KMT2AACHEL3MBTL1 | |
| SCHEMBL2515116 | 0.85 | AOX1 (0.66) | AOX1MEN1KMT2AACHEL3MBTL1 | |
| SCHEMBL16260353 | 0.84 | AOX1 (0.52) | AOX1MEN1KMT2AACHEL3MBTL1 | |
| SCHEMBL779739 | 0.84 | AOX1 (0.64) | AOX1MEN1KMT2AACHEL3MBTL1 | |
| SCHEMBL5491426 | 0.84 | MEN1 (0.51) | AOX1MEN1KMT2AL3MBTL1 | |
| SCHEMBL5488227 | 0.83 | AOX1 (0.50) | AOX1MEN1KMT2AACHEL3MBTL1 | |
| SCHEMBL14809495 | 0.83 | AOX1 (0.51) | AOX1MEN1KMT2AACHEL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070087270-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SOLUTION SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-04-19 | — | — | US | disclosed |
| US-7169511-B2 | Nonaqueous electrolyte solution and nonaqueous electrolyte solution secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-01-30 | — | — | US | disclosed |
| US-20050014071-A1 | Nonaqueous electrolyte solution and nonaqueous electrolyte solution secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2005-01-20 | — | — | US | disclosed |
| US-6583177-B2 | Amidinophenol derivatives as leukotriene B4 (LTB4)antagonists, phospholipase A2 inhibitors, and trypsin inhibitors. | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-06-24 | — | — | US | disclosed |
| US-20020128315-A1 | Leukotriene B4 antagonist compounds and method for treatment | NAKAI HISAO (JP) | 2002-09-12 | — | — | US | disclosed |
| US-6262114-B1 | NOVEL AMIDINOPHENOL DERIVATIVES; INHIBITORS OF PHOSPHOLIPASE A2 AND/OR TRYPSIN | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-07-17 | — | — | US | disclosed |
| EP-0703216-B1 | Amidinophenol derivatives as protease inhibitors | ONO PHARMACEUTICAL CO (JP) | 1999-04-07 | — | — | EP | disclosed |
| EP-0703216-A1 | Amidinophenol derivatives as protease inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 1996-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128315-A1 | Leukotriene B4 antagonist compounds and method for treatment | LTB4R2, LTB4R, LTA4H | AOX1 417/4885MEN1 4125/4885KMT2A 3478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.